Skip to content
Teniposide
Vumon (teniposide) is a small molecule pharmaceutical. Teniposide was first approved as Vumon on 1992-07-14. It is used to treat lung neoplasms, lymphoid leukemia, and small cell carcinoma in the USA. It is known to target DNA topoisomerase 2-alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teniposide
Tradename
Company
Number
Date
Products
VUMONHQ Specialty PharmaN-020119 DISCN1992-07-14
1 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
lung neoplasms—D008175C34.90
lymphoid leukemia—D007945C91
small cell carcinoma—D018288—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CB: Podophyllotoxin derivatives, antineoplastic drugs
— L01CB02: Teniposide
HCPCS
Code
Description
Q2017
Injection, teniposide, 50 mg
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carcinoid heart diseaseD002275EFO_1001769——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.8—3——14
Pancreatic neoplasmsD010190EFO_0003860C25—1——12
DiarrheaD003967HP_0002014R19.7—1———1
Biliary tract neoplasmsD001661C24.9—1———1
Ulcerative colitisD003093EFO_0000729K51—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD0043474————4
Hepatic insufficiencyD0485502————2
Renal insufficiencyD051437HP_0000083N191————1
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTENIPOSIDE
INNteniposide
Description
Teniposide (trade name Vumon) is a chemotherapeutic medication used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Identifiers
PDB—
CAS-ID29767-20-2
RxCUI10362
ChEMBL IDCHEMBL452231
ChEBI ID—
PubChem CID452548
DrugBankDB00444
UNII ID957E6438QA (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TOP2A
TOP2A
Organism
Homo sapiens
Gene name
TOP2A
Gene synonyms
TOP2
NCBI Gene ID
7153
Protein name
DNA topoisomerase 2-alpha
Protein synonyms
DNA gyrase, DNA topoisomerase (ATP-hydrolyzing), DNA topoisomerase II, 170 kD, DNA topoisomerase II, alpha isozyme, topoisomerase (DNA) II alpha 170kDa
Uniprot ID
Q9UQP9
Mouse ortholog
Top2a (21973)
DNA topoisomerase 2-alpha (Q01320)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,311 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,622 adverse events reported
View more details